Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $1,001.46
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 15, 26 | Fraga Francisco | officer: EVP, CIO and CTO | S-Sale | 800 @ $995.80 | $797.1K |
| Oct 20, 26 |
| Mizuho |
| maintain |
| Neutral |
| Neutral |
| Oct 16, 26 | UBS | maintain | Buy | Buy |
| Oct 7, 26 | Leerink Partners | maintain | Outperform | Outperform |
| Sep 14, 26 | RBC Capital | maintain | Sector Perform | Sector Perform |
| Aug 19, 26 | Barclays | maintain | Overweight | Overweight |
| Aug 11, 26 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| Aug 6, 26 | TD Cowen | maintain | Buy | Buy |
| Aug 6, 26 | UBS | maintain | Buy | Buy |
| Aug 6, 26 | Evercore ISI Group | maintain | Outperform | Outperform |
| Sep 8, 26 |
| Rutledge Napoleon B Jr |
| officer: SVP, Controller & CAO |
| S-Sale |
| 111 @ $891.45 |
| $98.95K |
| Aug 7, 26 | Srinivasan Ramesh (Nmn) | officer: EVP and Chief Strategy Officer | A-Award | 368 | — |
| Aug 10, 26 | Lerman Bradley E | director | S-Sale | 301 @ $892.33 | $268.6K |
| Aug 1, 26 | Srinivasan Ramesh (Nmn) | officer: EVP and Chief Strategy Officer | 0 | — |
| Aug 1, 26 | Srinivasan Ramesh (Nmn) | officer: EVP and Chief Strategy Officer | 316 | — |
| Jul 22, 26 | Hinton James H. | director | A-Award | 277 | — |
| Jul 22, 26 | Doughtie Lynne M | director | A-Award | 277 | — |
Stock news · updated daily
McKesson Corp. stands out as an asset-heavy distributor poised to benefit from AI-driven prescription automation and expedited FDA rare-disease drug approvals. MCK's specialty and oncology segment, with 41% YoY profit growth and superior margins, insulates it from AI disintermediation risks affecting vertically integrated telehealth peers. Despite materially faster EPS growth (24% forward GAAP), MCK trades at only a modest premium (forward P/E 25.75x), with a PEG ratio of 0.55x, suggesting undervaluation.
Carnegie Investment Counsel raised its position in McKesson Corporation (NYSE: MCK) by 56.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,242 shares of the company's stock after acquiring an additional 1,525 shares during the quarter. Carnegie Investment Counsel's holdings in McKesson
The latest trading day saw McKesson (MCK) settling at $1, representing a -1.42% change from its previous close.
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 94 cents per share of common stock. The dividend will be payable on January 4, 2027, to shareholders of record on December 1, 2026. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufact.
In the latest trading session, McKesson (MCK) closed at $1, marking a +1.95% move from the previous day.
IFP Advisors Inc lifted its position in McKesson Corporation (NYSE: MCK) by 10.7% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,514 shares of the company's stock after purchasing an additional 728 shares during the period. IFP
Counterpoint Mutual Funds LLC boosted its stake in shares of McKesson Corporation (NYSE: MCK) by 18.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,235 shares of the company's stock after purchasing an additional 1,788 shares during the quarter. McKesson comprises 0.8%
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | 9.56 | 9.93 | Beat 3.9% | $105.4B |
| May 7, 2026 | 11.56 | 11.69 | Beat 1.1% | $96.30B |
| Feb 4, 2026 | 9.17 | 9.34 | Beat 1.9% | $106.2B |
| Nov 5, 2025 | 9.03 | 9.86 | Beat 9.2% | $103.2B |
| Aug 6, 2025 | 8.14 | 8.26 | Beat 1.5% | $97.83B |
| May 8, 2025 | 9.83 | 10.12 | Beat 3.0% | $90.82B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 19, 2026 | 2026-10-19 16:39:47 | View |
| 8-K | Oct 6, 2026 | 2026-10-06 08:03:53 | View |
| 4 | Sep 10, 2026 | 2026-09-10 13:13:01 | View |
| 8-K | Aug 28, 2026 | 2026-08-28 16:05:30 | View |
| 4 | Aug 11, 2026 | 2026-08-11 14:06:12 | View |
| 4 | Aug 11, 2026 | 2026-08-11 14:05:55 | View |
| 3 | Aug 10, 2026 | 2026-08-10 17:26:38 | View |
| 10-Q | Aug 5, 2026 | 2026-08-05 17:29:27 | View |
| 8-K | Aug 5, 2026 | 2026-08-05 16:06:03 | View |
| 8-K | Jul 24, 2026 | 2026-07-24 16:10:19 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | MCK | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 26.7x | 25.7x · sector 20.7x | Elevated |
| Forward P/E (FY27E) | 22.4x | EPS est. 44.64 | Discount |
| Price / Book | -28.0x | -34.9x | Discount |
| Price / Sales | 0.3x | 0.2x | Elevated |
| EV / EBITDA | 16.8x | 15.1x | In line |
| Return on equity | -194.4% | — | Weak |
| Gross margin | 3.6% | 4.0% | In line |
| Debt / Equity | -2.76 | -3.71 | Conservative |
| Piotroski / Altman Z | 7/9 | Z 5.93 | Safe zone |
Discounted cash flow model
FY2026 · 10-K disclosure
FY2020 · 10-K disclosure
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 67.01 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 84.53 | Oscillator | Sell |
| Williams %R (14) | -22.65 | Oscillator | Neutral |
| MACD (12, 26, 9) | 34.33 (Hist 5.68) | Oscillator | Strong Buy |
| Average Directional Index (14) | 32.19 (+DI 33.6 / -DI 16.7) | Trend | Strong Buy |
| EMA 20 | 963.60 | MA | Strong Buy |
| SMA 20 | 948.05 | MA | Strong Buy |
| EMA 50 | 918.97 | MA | Strong Buy |
| SMA 50 | 910.11 | MA | Strong Buy |
| SMA 200 | 858.73 | MA | Strong Buy |